PDCD1 and non-small cell lung carcinoma: Ivonescimab (AK112), a bispecific antibody that targets PD‐1 and VEGF, has been assessed as a first or second‐line treatment for advanced NSCLC, with preliminary findings indicating notable antitumor efficacy and a manageable safety profile [83].